SCHEMBL8140353

SCHEMBL8140353

C[C@H](NC(=O)CNC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
CTSS P25774 6/20 0.43
CTSK P43235 6/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
CYP2D6 P10635 1/20 0.39
SDCBP O00560 1/20 0.37
SDC2 P34741 1/20 0.37
APLNR P35414 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31314679 1.00 KMT2A (0.49) KMT2AMEN1GAACTSSCTSK
SCHEMBL31069956 0.97 KMT2A (0.46) KMT2AMEN1GAACTSSCTSK
SCHEMBL8903579 0.88 CTSS (0.53) KMT2AMEN1GAACTSSCTSK
SCHEMBL23332499 0.87 NPSR1 (0.44) KMT2AMEN1GAACTSSCTSK
SCHEMBL30029922 0.87 NPSR1 (0.44) KMT2AMEN1GAACTSSCTSK
SCHEMBL23629905 0.86 CTSS (0.51) KMT2AMEN1GAACTSSCTSK
SCHEMBL23629908 0.86 CTSS (0.51) KMT2AMEN1GAACTSSCTSK
SCHEMBL28840562 0.85 KMT2A (0.47) KMT2AMEN1GAACTSSCTSK
SCHEMBL16667763 0.85 CA12 (0.49) KMT2AMEN1GAACTSSCTSK
SCHEMBL8251498 0.84 CA1 (0.46) KMT2AMEN1GAACTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114891071-A Novel polypeptides and therapeutic uses thereof 鸿绪生物科技(嘉善)有限公司 2022-08-12 CN disclosed
US-8741834-B2 Dipeptoid prodrugs and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-06-03 US disclosed
US-20110294719-A1 DIPEPTOID PRODRUGS AND THE USE THEREOF Bayer Schering Pharma 2011-12-01 US disclosed
EP-1042298-A1 POLYCYCLIC ALPHA-AMINO-EPSILON-CAPROLACTAMS AND RELATED COMPOUNDS Elan Pharmaceuticals, Inc. (US) 2000-10-11 EP disclosed
WO-1999032453-A1 POLYCYCLIC α-AMINO-⊂-CAPROLACTAMS AND RELATED COMPOUNDS ELAN PHARMACEUTICALS, INC. (US) 1999-07-01 WO disclosed
EP-0414533-A1 Use of iodopropargyl esters of alpha-amino acid derivatives as antimicrobial agents ROHM AND HAAS COMPANY (US) 1991-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294719-A1 DIPEPTOID PRODRUGS AND THE USE THEREOF DPP4, DPP3, DNPEP KMT2A 3242/4885MEN1 2410/4885GAA 2730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.